Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. SYMTUZA (cobicistat/ darunavir (éthanolate de)/ emtricitabine/ ténofovir alafén...)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

SYMTUZA (cobicistat/ darunavir (éthanolate de)/ emtricitabine/ ténofovir alafén...)

Medicine - Posted on Sep 12 2019
Active substance (DCI)
  • cobicistat
  • darunavir (éthanolate de)
  • emtricitabine
  • ténofovir alafénamide (fumarate de)
history (2)
  • 7/11/18

    SYMTUZA (cobicistat/ darunavir (éthanolate de)/ emtricitabine/ ténofovir alafén...)

    Intérêt clinique insuffisant dans le traitement de l’infection chronique par le VIH-1 SYMTUZA a l’AMM pour le traitement de ...
    icône flèche
  • 7/11/18

    SYMTUZA (darunavir /cobicistat /emtricitabine /tenofovir alafenamide), antiviral combination

    Clinical benefit insufficient in the treatment of chronic HIV-1 infection SYMTUZA has marketing authorization (MA) for the t...
    icône flèche
Technical information
ATC code
  • J05AR
Manufacturer
JANSSEN-CILAG
Presentation

SYMTUZA 800 mg/150 mg/200 mg/10 mg, comprimé pelliculé (code CIS : 67413102)
1 flacon avec fermeture de sécurité enfant de 30 comprimés - Code CIP : 34009 301 150 6 0

All our publications
    Drug therapy Immunologic deficiency syndromes Paediatrics Sexually transmitted diseases Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
thQUxXUYJrprAQLt